Press coverage about Rhythm Pharmaceuticals (NASDAQ:RYTM) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rhythm Pharmaceuticals earned a news impact score of 0.04 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.2975307196008 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of brokerages have recently issued reports on RYTM. Bank of America Corporation began coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $30.00 price objective for the company. Needham & Company LLC began coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued a “buy” rating and a $32.00 price objective for the company. Cowen and Company began coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued an “outperform” rating and a $40.00 price objective for the company. Finally, Morgan Stanley assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, October 30th. They issued an “equal weight” rating and a $23.00 price objective for the company.
Rhythm Pharmaceuticals (NASDAQ:RYTM) opened at $24.21 on Friday. Rhythm Pharmaceuticals has a 52 week low of $21.38 and a 52 week high of $33.81.
In other Rhythm Pharmaceuticals news, Director David P. Meeker acquired 25,000 shares of the stock in a transaction on Tuesday, October 10th. The stock was acquired at an average price of $17.00 per share, for a total transaction of $425,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James E. Flynn acquired 355,000 shares of the stock in a transaction on Tuesday, October 10th. The shares were acquired at an average price of $17.00 per share, with a total value of $6,035,000.00. The disclosure for this purchase can be found here. Insiders have purchased 1,285,000 shares of company stock valued at $21,845,000 over the last ninety days.
WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-rhythm-pharmaceuticals-rytm-share-price.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.